In this week's DermwireTV, new NIH data looks at the association between AD and several health conditions; a study evaluates the effect of lebrikizumab monotherapy in patients with moderate-to-severe AD over 16 weeks; and Andrew Mastro provides tips on how to optimize the first 5 minutes with a patient.
